Price Alert: Shares of Cerevel (CERE) Trade 9.27% Higher at Midday August 5

Equities Staff  |

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) has gained $2.61 (9.27%) and sits at $30.14, as of 11:49:02 est on August 5.

332,543 shares exchanged hands.

The Company has risen 15.69% over the last 5 days and shares lost 3.69% over the last 30 days.

Cerevel expects its next earnings on 2022-11-09.

For technical charts, analysis, and more on Cerevel visit the company profile.

About Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson's, epilepsy, schizophrenia and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

To get more information on Cerevel Therapeutics Holdings Inc and to follow the company's latest updates, you can visit the company's profile page here: Cerevel Therapeutics Holdings Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content